Fluorescence lifetime assays: current advances and applications in drug discovery

被引:13
作者
Pritz, Stephan [2 ]
Doering, Klaus [3 ]
Woelcke, Julian [1 ]
Hassiepen, Ulrich [1 ]
机构
[1] Novartis Pharma AG, CPC Expertise Platform Proteases EPP, NIBR, CH-4002 Basel, Switzerland
[2] Biosyntan GmbH, Berlin, Germany
[3] AssayMetr Ltd, Cardiff, Wales
关键词
assay; compound interference; drug discovery; enzyme inhibition; fluorescence lifetime; kinase; phosphatase; protease; KINASE INHIBITORS; PROTEIN-KINASES; PROTEASES; TECHNOLOGY; SITE;
D O I
10.1517/17460441.2011.571250
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Fluorescence lifetime assays complement the portfolio of established assay formats available in drug discovery, particularly with the recent advances in microplate readers and the commercial availability of novel fluorescent labels. Fluorescence lifetime assists in lowering complexity of compound screening assays, affording a modular, toolbox-like approach to assay development and yielding robust homogeneous assays. Areas covered: To date, materials and procedures have been reported for biochemical assays on proteases, as well as on protein kinases and phosphatases. This article gives an overview of two assay families, distinguished by the origin of the fluorescence signal modulation. Expert opinion: The pharmaceutical industry demands techniques with a robust, integrated compound profiling process and short turnaround times. Fluorescence lifetime assays have already helped the drug discovery field, in this sense, by enhancing productivity during the hit-to-lead and lead optimization phases. Future work will focus on covering other biochemical molecular modifications by investigating the detailed photo-physical mechanisms underlying the fluorescence signal.
引用
收藏
页码:663 / 670
页数:8
相关论文
共 37 条
[1]  
Abbenante Giovanni, 2005, Med Chem, V1, P71, DOI 10.2174/1573406053402569
[2]  
Barrett AJ, 2004, HDB PROTEOLYTIC ENZY
[3]   Fragment-Based Screening by Biochemical Assays: Systematic Feasibility Studies with Trypsin and MMP12 [J].
Boettcher, Andreas ;
Ruedisser, Simon ;
Erbel, Paulus ;
Vinzenz, Daniela ;
Schiering, Nikolaus ;
Hasiepen, Ulrich ;
Rigollier, Pascal ;
Mayr, Lorenz M. ;
Woelcke, Julian .
JOURNAL OF BIOMOLECULAR SCREENING, 2010, 15 (09) :1029-1041
[4]  
Chen T., 2009, A Practical Guide to Assay Development and High-Throughput Screening, DOI DOI 10.1201/9781420070514
[5]   Protein kinases - the major drug targets of the twenty-first century? [J].
Cohen, P .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (04) :309-315
[6]  
Comley J., 2003, DRUG DISCOV WORLD, V4, P91
[7]  
COMLEY J, 2010, DRUG DISCOV WORLD, V11, P71
[8]   A Fluorescence Lifetime-Based Assay for Protease Inhibitor Profiling on Human Kallikrein 7 [J].
Doering, Klaus ;
Meder, Gabriele ;
Hinnenberger, Manuela ;
Woelcke, Julian ;
Mayr, Lorenz M. ;
Hassiepen, Ulrich .
JOURNAL OF BIOMOLECULAR SCREENING, 2009, 14 (01) :1-9
[9]   Emerging principles in protease-based drug discovery [J].
Drag, Marcin ;
Salvesen, Guy S. .
NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (09) :690-701
[10]   Aspartic proteases in drug discovery [J].
Eder, Joerg ;
Hommel, Ulrich ;
Cumin, Frederic ;
Martoglio, Bruno ;
Gerhartz, Bernd .
CURRENT PHARMACEUTICAL DESIGN, 2007, 13 (03) :271-285